FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016504951> ?p ?o ?g. }

• W2016504951 endingPage "248" @default.
• W2016504951 startingPage "244" @default.
• W2016504951 abstract "To evaluate the safety and efficacy of epoetin alfa administered in extended-dosing intervals to a target hemoglobin (Hb) level not exceeding 12.0 g/dL for the treatment of anemia in subjects with chronic kidney disease (CKD) not on dialysis.An open-label, randomized, multicenter, controlled study consisting of a 1-week screening phase and a 26-week open-label treatment phase.Twenty-seven long term care (LTC) facilities in the United States.Subjects with CKD who were not receiving dialysis, who had not received an erythropoiesis-stimulating agent for 8 weeks before screening, and whose Hb levels were lower than 11.0 g/dL at screening were eligible.In the epoetin alfa group, subjects were administered 20,000 international units epoetin alfa subcutaneously every 2 weeks (Q2W). Dosing was based on the Hb concentration measurement obtained by HemoCue Hb201+System (Quest Diagnostics; Madison, NJ) at the time of the scheduled dose. When the Hb concentration was 11.0 to 11.5 g/dL on 2 consecutive biweekly measurements, the dose was doubled and administered on the day that the second consecutive measurement was obtained. The dosing interval was then extended to every 4 weeks (Q4W). Subjects in the standard of care (SOC) group received treatment for their anemia according to the practice of the LTC facility.Study visits were every 2 weeks, at which time blood was drawn and used for efficacy analysis. Measurements included: the Hb concentration change from baseline to the end of the study; the proportion of subjects who achieved an Hb response (defined as 2 consecutive Hb measurements at least 1.0 g/dL greater than baseline or 2 consecutive Hb measurements ≥11.0 g/dL at any time during the study); the time to the Hb response; the proportion of subjects who received a transfusion and the number of units of transfused; the proportion of epoetin alfa-treated subjects converting to Q4W dosing; and the proportion of subjects who converted to Q4W dosing and remained on Q4W dosing through the end of the study.A total of 157 subjects were randomized: 118 subjects to the epoetin alfa group and 39 to the SOC group. The mean change in Hb was significantly greater in the epoetin alfa group (0.9 g/dL) compared with the SOC group (0.3 g/dL) (P = .006). A significantly greater percentage of subjects achieved a Hb response in the epoetin alfa group (85.1%) compared with the SOC group (53.8%) (P < .001). The time to achieve a Hb response was significantly shorter in the epoetin alfa group (41 days) than in the SOC group (114 days) (P < .0001). There were no transfusions in the SOC group, whereas 4 subjects (3.5%) required transfusions in the epoetin alfa group. Of the 114 subjects receiving epoetin alfa, 33 (28.9%) subjects were converted to Q4W dosing, and all subjects who converted were able to be maintained on this schedule.The administration of epoetin alfa in extended-dosing intervals of Q2W followed by Q4W was safe and effective in the treatment of anemia in subjects with CKD who reside in LTC facilities." @default.
• W2016504951 created "2016-06-24" @default.
• W2016504951 creator A5024409404 @default.
• W2016504951 creator A5046899948 @default.
• W2016504951 creator A5048926730 @default.
• W2016504951 creator A5074099866 @default.
• W2016504951 creator A5082269036 @default.
• W2016504951 date "2012-03-01" @default.
• W2016504951 modified "2023-10-04" @default.
• W2016504951 title "An Open-Label, Randomized, Multicenter, Controlled Study of Epoetin Alfa for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care Setting" @default.
• W2016504951 cites W1516581565 @default.
• W2016504951 cites W1554432499 @default.
• W2016504951 cites W1809229150 @default.
• W2016504951 cites W1974218285 @default.
• W2016504951 cites W2014074349 @default.
• W2016504951 cites W2019130503 @default.
• W2016504951 cites W2023395406 @default.
• W2016504951 cites W2083237996 @default.
• W2016504951 cites W2094875169 @default.
• W2016504951 cites W2122350078 @default.
• W2016504951 cites W2132984927 @default.
• W2016504951 cites W2138393925 @default.
• W2016504951 cites W2139537558 @default.
• W2016504951 cites W2141772399 @default.
• W2016504951 cites W2158947129 @default.
• W2016504951 doi "https://doi.org/10.1016/j.jamda.2010.09.009" @default.
• W2016504951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21450214" @default.
• W2016504951 hasPublicationYear "2012" @default.
• W2016504951 type Work @default.
• W2016504951 sameAs 2016504951 @default.
• W2016504951 citedByCount "11" @default.
• W2016504951 countsByYear W20165049512012 @default.
• W2016504951 countsByYear W20165049512014 @default.
• W2016504951 countsByYear W20165049512017 @default.
• W2016504951 countsByYear W20165049512019 @default.
• W2016504951 countsByYear W20165049512023 @default.
• W2016504951 crossrefType "journal-article" @default.
• W2016504951 hasAuthorship W2016504951A5024409404 @default.
• W2016504951 hasAuthorship W2016504951A5046899948 @default.
• W2016504951 hasAuthorship W2016504951A5048926730 @default.
• W2016504951 hasAuthorship W2016504951A5074099866 @default.
• W2016504951 hasAuthorship W2016504951A5082269036 @default.
• W2016504951 hasConcept C126322002 @default.
• W2016504951 hasConcept C141071460 @default.
• W2016504951 hasConcept C168563851 @default.
• W2016504951 hasConcept C2776164570 @default.
• W2016504951 hasConcept C2777288759 @default.
• W2016504951 hasConcept C2778248108 @default.
• W2016504951 hasConcept C2778534260 @default.
• W2016504951 hasConcept C2778653478 @default.
• W2016504951 hasConcept C2778917026 @default.
• W2016504951 hasConcept C2779978075 @default.
• W2016504951 hasConcept C2781404941 @default.
• W2016504951 hasConcept C71924100 @default.
• W2016504951 hasConceptScore W2016504951C126322002 @default.
• W2016504951 hasConceptScore W2016504951C141071460 @default.
• W2016504951 hasConceptScore W2016504951C168563851 @default.
• W2016504951 hasConceptScore W2016504951C2776164570 @default.
• W2016504951 hasConceptScore W2016504951C2777288759 @default.
• W2016504951 hasConceptScore W2016504951C2778248108 @default.
• W2016504951 hasConceptScore W2016504951C2778534260 @default.
• W2016504951 hasConceptScore W2016504951C2778653478 @default.
• W2016504951 hasConceptScore W2016504951C2778917026 @default.
• W2016504951 hasConceptScore W2016504951C2779978075 @default.
• W2016504951 hasConceptScore W2016504951C2781404941 @default.
• W2016504951 hasConceptScore W2016504951C71924100 @default.
• W2016504951 hasIssue "3" @default.
• W2016504951 hasLocation W20165049511 @default.
• W2016504951 hasLocation W20165049512 @default.
• W2016504951 hasOpenAccess W2016504951 @default.
• W2016504951 hasPrimaryLocation W20165049511 @default.
• W2016504951 hasRelatedWork W1590171812 @default.
• W2016504951 hasRelatedWork W1964706798 @default.
• W2016504951 hasRelatedWork W2007053419 @default.
• W2016504951 hasRelatedWork W2014074349 @default.
• W2016504951 hasRelatedWork W2040029744 @default.
• W2016504951 hasRelatedWork W2067595666 @default.
• W2016504951 hasRelatedWork W2100854655 @default.
• W2016504951 hasRelatedWork W2903992936 @default.
• W2016504951 hasRelatedWork W4254879415 @default.
• W2016504951 hasRelatedWork W78241025 @default.
• W2016504951 hasVolume "13" @default.
• W2016504951 isParatext "false" @default.
• W2016504951 isRetracted "false" @default.
• W2016504951 magId "2016504951" @default.
• W2016504951 workType "article" @default.